79069-16-2

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 2177-63-1 (S)-2-amino-4-(benzyloxy)-4-oxobutanoic acid 
• 79069-52-6 N-Boc-L-aspartic aldehyde β-benzyl ester 
• 118517-08-1 (S)-3-tert-Butoxycarbonylamino-4-isopropoxycarbonyloxy-4-oxo-butyric acid benzyl ester 
• 7536-58-5 BOC-L-aspartic acid 4-benzyl ester 
• 138108-83-5 C₂₀H₂₉NO₆ 
• 543-27-1 isobutyl chloroformate 
• 118943-18-3 4-(phenylmethyl) N-[(1,1-dimethylethoxy)carbonyl]-1(2,5-dioxo-1-pyrrolidinyl) L-aspartate 
• 100-51-6 benzyl alcohol 
• 84890-97-1 (S)-3-tert-Butoxycarbonylamino-4-isobutoxycarbonyloxy-4-oxo-butyric acid benzyl ester 

Downstream Products

• 517877-32-6 (S)-N-[(tert-butoxy)carbonyl]-γ-(3-benzoylthymin-1-yl)-β-homoalanine benzyl ester 
• 636604-13-2 3-amino-4-(5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-butyric acid benzyl ester 
• 556069-33-1 3-[2-(9H-fluoren-9-ylmethoxycarbonylamino)-acetylamino]-4-(5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-butyric acid benzyl ester 
• 151139-89-8 phenylmethyl (4S)-3-[(1,1-dimethylethoxy)carbonyl]-2,2-dimethyl-4-oxazolidineacetate 
• 161745-47-7 benzyl 3(S)-<(tert-butoxycarbonylamino)>-4-p-toluenesulfonyl-1-butyrate 
• 136703-59-8 (3S)-3-[(tert-butoxycarbonyl)amino]-4-hydroxybutanoic acid methyl ester 
• 83345-44-2 3-tert-butoxycarbonylamino-4-hydroxy-butyric acid 
• 142895-04-3 Boc-β³-Cys(Ac)-OBn 
• 1429399-44-9 benzyl (3S)-4-{[(2R)-2-amino-3-ethoxy-3-oxopropyl]thio}-3-[(tert-butoxycarbonyl)amino]butanoate 
• 221106-60-1 (S)-3-(tert-butoxycarbonylamino)-4-(tert-butyldimethylsiloxy)butyric acid benzyl ester 
• 79069-52-6 N-Boc-L-aspartic aldehyde β-benzyl ester 

Relevant academic research and scientific papers

CATHEPSIN CYSTEINE PROTEASE INHIBITORS

This invention relates to deuterated compounds which are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.

COMPOSITIONS AND METHODS FOR MODULAR CONTROL OF BIOORTHOGONAL LIGATION

The present invention provides a compound having the structure: Formula (I) wherein R1 is H or a protecting group; R2 and R3 are each independently H, halo, C1-C6 alkyl, C2-C6 al

Design and Optimization of an Acyclic Amine Series of TRPV4 Antagonists by Electronic Modulation of Hydrogen Bond Interactions

Investigation of TRPV4 as a potential target for the treatment of pulmonary edema associated with heart failure generated a novel series of acyclic amine inhibitors displaying exceptional potency and PK properties. The series arose through a scaffold hopp

Lipidated cyclopropenes via a stable 3-N spirocyclopropene scaffold

Lipidated cyclopropenes serve as useful bioorthogonal reagents for imaging cell membranes due to the cyclopropene's small size and ability to ligate with pro-fluorescent tetrazines. Previously, the lipidation of cyclopropenes required modification at the C3 position because methods to append lipids at C1/C2 were not available. Herein, we describe C1/C2 lipidation with the biologically active lipid ceramide and a common phospholipid using a cyclopropene scaffold whose reactivity with 1,2,4,5-tetrazines has been caged.

Rational design, synthesis and in vitro evaluation of novel exo-methylene butyrolactone salicyloylamide as NF-κB inhibitor

(?)-Dehydroxymethylepoxyquinomicin ((?)-DHMEQ, 1) is a specific inhibitor of NF-κB. It binds to SH group in the specific cysteine residue of NF-κB components with its epoxide moiety to inhibit DNA binding. In the present research, we have designed and synthesized an epoxide-free analog called (S)-β-salicyloylamino-α-exo-methylene-?-butyrolactone (SEMBL, 3). SEMBL inhibited DNA binding of NF-κB component p65 in vitro. It inhibited LPS-induced NF-κB activation, iNOS expression, and inflammatory cytokine secretions. It also inhibited NF-κB and cellular invasion in ovarian carcinoma ES-2 cells. Moreover, its stability in aqueous solution was greatly enhanced compared with (?)-DHMEQ. Thus, SEMBL has a potential to be a candidate for a new anti-inflammatory and anticancer agent.

Cathepsin K inhibitors and use thereof

The invention relates to compounds and pharmaceutical compositions thereof for treatment or prevention of cathepsin dependent diseases; the compounds and the compositions comprising the compounds can be used as bone absorption inhibitors for treatment of related diseases, wherein the cathepsin includes, but is not limited to, cathepsin K.

Novel heteroaryl butanoic acid derivatives

The present invention describes novel heteroaryl butanoic acid derivatives that are good drug candidates especially with regard to leukotriene A4 hydrolase (LTA4H). The present invention also relates to pharmaceutical compositions comprising said novel he

HETEROARYL BUTANOIC ACID DERIVATIVES AS LTA4H INHIBITORS

The present invention describes novel heteroaryl butanoic acid derivatives that are good drug candidates especially with regard to leukotriene A4 hydrolase (LTA4H). The present invention also relates to pharmaceutical compositions comprising said novel he

3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH

The invention is directed to a formula (I), or a pharmamceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

Novel thiol- and thioether-containing amino acids: Cystathionine and homocysteine families

Natural l-homocysteine and l,l-cystathionine, along with a series of unnatural analogues, have been prepared from l-aspartic and l-glutamic acid. Manipulation of the protected derivatives provided ω-iodoamino acids, which were used in thioalkylation react